Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Magrolimab - Forty Seven

Drug Profile

Magrolimab - Forty Seven

Alternative Names: 5F9; GS-4721; Hu5F9 G4; Magrolimab - Forty-Seven/Stanford-University; ONO 7913

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer Forty Seven; Gilead Sciences; M. D. Anderson Cancer Center; Merck KGaA; Merck Sharp & Dohme; National Cancer Institute (USA); Ono Pharmaceutical; Roche; Stanford University; University of California at San Francisco
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Head and neck cancer; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours; Triple negative breast cancer
  • Phase I Brain cancer; Cutaneous B-cell lymphoma; Lymphoma; Neuroblastoma; Osteosarcoma; Pancreatic cancer
  • No development reported Ovarian cancer

Most Recent Events

  • 01 Mar 2024 Gilead Sciences suspends a phase II trial for Head and neck cancer (Combination therapy, Late-stage disease, Locally recurrent, Metastatic disease, Second-line therapy or greater) in the USA (IV, Infusion), as per PI request (NCT06046482)
  • 27 Feb 2024 Gilead Sciences terminates phase-II ACT-AML-101 trial for Acute myeloid leukaemia (Combination therapy, First-line therapy) in United Kingdom (IV) (ISRCTN71474257)
  • 24 Feb 2024 University of California and Gilead Sciences terminates a Phase-I clinical trials in Brain cancer (Metastatic disease, In children, Recurrent) in USA (IV) due to partial clinical hold by FDA (NCT05169944)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top